SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-009746
Filing Date
2022-02-28
Accepted
2022-02-28 16:26:25
Documents
14
Period of Report
2022-02-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea156235-8k_nektartherap.htm   iXBRL 8-K 36131
2 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 20 ea156235ex99-1_nektartherap.htm EX-99.1 111406
3 GRAPHIC ex99-1_001.jpg GRAPHIC 6270
  Complete submission text file 0001213900-22-009746.txt   343020

Data Files

Seq Description Document Type Size
4 XBRL LABEL FILE nktr-20220228_lab.xml EX-101.LAB 34476
5 XBRL PRESENTATION FILE nktr-20220228_pre.xml EX-101.PRE 22591
6 XBRL SCHEMA FILE nktr-20220228.xsd EX-101.SCH 3027
8 EXTRACTED XBRL INSTANCE DOCUMENT ea156235-8k_nektartherap_htm.xml XML 3495
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

IRS No.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 22690093
SIC: 2834 Pharmaceutical Preparations